JERSEY CITY, N.J., Sept. 28, 2017 /PRNewswire/ -- TrialScope, the global leader in clinical trial transparency and
The survey asked sponsors about their current approach to trial results summaries and their plans for sharing summaries in the future. TrialScope's Chief Strategy Officer, Thomas Wicks, presented highlights of the results in a session titled "How to distribute trial results summaries to patients?" on September 26th.
"There is a growing industry-wide understanding that patients have a right to receive information on the results of clinical trials in a language and format that is clear, concise, and factual," said Wicks. "This is not only an evolving requirement, but also an opportunity to engage directly with trial participants and the patient community and make a difference in people's lives."
Key takeaways from the survey include:
"ClinicalTrials.gov currently lists more than 250,000 trials from around the world," continued Wicks. "It's encouraging to see we're headed in the right direction, but there is still progress to be made."
About TrialScope TrialScope simplifies the complexities of clinical trial transparency. TrialScope's award-winning, proven solutions have been implemented successfully and rigorously tested in the most complex environments and are managing disclosures for sponsors that are responsible for over 35% of industry sponsored clinical trials posted on clinicaltrials.gov. The company's market-driven solutions and expertise enable sponsors to improve performance, mitigate compliance risk, and ultimately optimize efficiencies with clinical content lifecycle management tools, expertise and processes. TrialScope technologies are offered via a validation-ready SaaS platform hosted in a private cloud.
Contact: Alyson Kuritz 908-892-7149 firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/trialscope-tackles-issue-of-sharing-clinical-trial-results-with-patients-at-cbi-conference-presents-sponsor-survey-findings-300527550.html
Subscribe to our Free Newsletters!
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...
Encephalocele is a birth defect where a sac like protrusion of brain and covering membranes occurs ...View All